Dr. Prasun Chakraborty is the CEO and Founder of Genevation/GeneevationUS, a groundbreaking biotechnology company pioneering the development of personalized cancer vaccines. Dr Chakraborty is a visionary leader and innovator in the field of biotechnology, specializing in the development of cutting-edge personalized cancer therapies. Dr Chakraborty spearheads advancements in AI-driven neoantigen discovery and mRNA-based therapeutics, driving transformative solutions in precision oncology. With a distinguished career in oncology research and translational medicine, Dr. Chakraborty has led innovations aimed at revolutionizing cancer treatment through rapid, patient-specific vaccine platforms. His work emphasizes cost-effective, scalable solutions that enhance treatment efficacy while minimizing side effects. Dr. Chakraborty's leadership has propelled Genevation through successful preclinical trials targeting lung, colon, and skin cancers. The company's innovative, cell-free vaccine platform has garnered attention for its two-week development timeline and impressive tumor regression results. A passionate advocate for patient-centric biotech, Dr. Chakraborty combines scientific expertise with entrepreneurial vision, aiming to redefine global standards in cancer care.
- Building up AI mediated identification and screening of Neo-antigen.- Using Cell-free platform to speed up development of personalized cancer vaccines - Affinity based mRNA purification method